Net Medical Xpress Solutions Inc (PK) (NMXS) 銘柄情報

again it needs to reverse the ongoing trend.....
positive eps is the only way to support stock price,without eps positive and no reduction of the $4+ million allowance to cash,i believe it would be tough to see positive stock price movement anytime soon. again,i believe 2023 is an important pivotal year and prove: does nmxs 2021-2022 transformation real or just a head fake??

let's hope for the best, but with government stopping testing, and pandemy showing up again, and testing for other illness and virusses becoming more important also, they could be in good position right now....

last 3 q trends are not good....
in term of revenue,eps,allowance of medical billing topped $4 million......and i believe likely it is about to lose money next q. i hope it can remain profitable and soon clear up its balance sheet,and if not, dead money for all 2023.

don't understand this....
However, up for a new steady climb probably....

i am here...
and watching.so far so good.

nobody home ?

Telemed Platform – This is the core system used to build a customized telemedicine management system for clients. Telemed has various components that can assist a company seeking to provide telemedicine services with a secure portal. It is most useful for telemedicine consults with a variety of exam modalities such as neurology, cardiology, neurosurgery, critical care, orthopedics and psychiatry features to document case studies. Telemed can be connected to mobile devices, tablets, laptops and stand- alone desktops.

$NMXS with great news coming off the holiday. Take a look, load up and hold. This news could get it back to to $.50 cents with the right support, STRONG Financials. ?? https://www.marketwatch.com/press-release/net-medical-to-sponsor-safari-run-in-support-of-global-health-partnership-2022-09-06

I strongly agree with you on this. The charts don't lie. Load up and hold. Impressed with their uptrend after Quarter 1 results.

insert-text-here

the chart is strong. And the fundamentals are stronger.

politics of covid funds.....
https://www.zerohedge.com/covid-19/federal-government-stop-paying-covid-shots-tests-and-treatments

q2 preliminary is out.....
revenue $1.56 million
net income $0.41 million
https://www.otcmarkets.com/stock/NMXS/news/Net-Medical-Reports-Strong-Y-O-Y-Q2-First-Half-Revenue-and-Net-Income?id=366425

word of caution.......
a good example is today's price action: less 15k shares can drove price down 10%,can you imagine what 50k shares market can do to it?
expect price volatility/gyration of up to 50% as we go forward.again,my price target is 60c posted many moon ago.will price change before next er,my guess
60c+ 33%(chance)
60c 33%
60c- 33%
or
a safer way to go:
wait until er(8/15/22) is out and make you decision than.

JUST PLAYING WITH SOME FIGURES ...
Based on common used rules - and such in a pretty conservative way - my personal estimation of the share value today ( based upon a total volume of 37.67 mio. shares ) is 0.60 $/sh. I took into account a reasonable growth of about 15 % each following
quarter , which brought me to a net profit of 3.4 mio.$ and an estimated turnover of , at least , 8.8 mio.$ for 2022 .
So, I apply a factor of 6.5 times the net profit ( 3.4 mio.$ x 6.5 = 22.1 mio.$ ) or a factor of 2.5 times the turnover (8.8 mio. $ x 2.5 = 22 mio.$) which shows me a similar result
( or 22 mio.$ / 37.67 mio.sh.=~ 0.60 $/sh. ).
These estimations might be totally incorrect if NMXS succeeds in keeping a growth rate of even only 50 % of the growth rate between T4/2021 and T1/2022 ... turnover + 132 % , gross profit +180 % and net profit + 152 % !!!
So T2/2022 will bring the transparency to conclude if the share-price is actually at its right value or will it leave all predictions behind and break through the 1 $ and even beyond it.

from the bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results...
my favorite quote:
"we remain active to look at technologies or companies, which are - which can bring which can complement our portfolio [indiscernible], is also is a new or emerging technologies, which have the potential to improve patient care on the decision time to results."
particularly,
"to improve patient care on the decision time to results."
a wild shot:
"telemed" platform??????plus clia and rural hospital network of nm(30+?) and az(??),with a combined population of up to 10 million.

https://seekingalpha.com/article/4492355-biomerieux-s-bmxmf-ceo-alexandre-merieux-on-q4-2021-results-earnings-call-transcript

this is how/when covid-19 diagnostic push got started by the
FDA back in 2020....
with the COVID-19 At-Anywhere Diagnostics Design-a-thon!
https://waters.crowdicity.com/hubbub/communitypage/22469
winners(top 12) are:
https://www.hhs.gov/blog/2021/04/01/covid-19-topx-tech-sprint-final-demos-showcasing-digital-diagnostic-tools.html
with
BRONZE(3rd place):
Net Medical Xpress Solutions, Inc: Net Medical's Telemed for COVID-19 Wireless Data
Treats COVID-19 test data capture as a Telemedicine consult problem: supports COVID-19 data collection and harmonization through questionnaires, order, and diagnostic forms. HL7 2.5.1 interface for export has been implemented and adopts standards like HTML5 and Web Bluetooth API. (Score: 30/35)

green lighting and endorsement of the 12 by the FDA??????the million dollar question and i think so.wooooowwwww.....

one of the drivers of the nmxs covid-19 business.....
"FDA urges COVID-19 test makers with EUAs to seek full authorizations"
https://www.medtechdive.com/news/fda-urges-covid-19-test-makers-euas-seek-full-authorization/620940/
my favorite:
"the FDA expects test developers to continue to routinely monitor and evaluate the performance impact of SARS-CoV-2 viral mutations on their diagnostics for as long as they are being offered. "

oooops....
blank page.

https://www.stockscores.com/chart.asp?TickerSymbol=nmxs&TimeRange=1825&Interval=m&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

$NMXS Net Medical Announces Joint Venture with Leading FDA Regulatory Firm, Smith AssociatesPress Release | 06/06/2022

ALBUQUERQUE, NM / ACCESSWIRE / June 6, 2022 / Net Medical (OTC Pink:NMXS) announced today it has formed a strategic partnership with Smith Associates for development and support of sophisticated clinical trials with multiple purposes such as the ability to specifically identify flu, common colds or COVID conditions.
Net Medical Xpress Solutions, Inc., Monday, June 6, 2022, Press release picture

The usability and clinical trial programs, which follow FDA guidelines, are jointly managed by Smith Associates and Net Medical. Smith Associates ensures that Net Medical has all the proper documentation needed to be compliant. Net Medical conducts trials in both English and Spanish, the two most important languages spoken in the U.S.

This is in response to increasing demand from both domestic and international manufacturers of COVID-19 tests to gain FDA approvals for Emergency Use Authorization (EUA) and 510k clearances. To gain approvals, medical device and related companies are subjected to rigorous evaluations and examinations by the FDA.

This partnership provides the necessary skills and experience to streamline the evaluation process for the manufacturers.

Smith Associates brings a combined 100-years of FDA regulatory background and experience for medical device and other medical companies seeking FDA approvals. This includes the most common route to clearance in the United States, the 510k submission (PMN), as well as Pre-Submissions, Pre-IDE, PMA, and Human Factors studies required for validation of the device by the intended use for inclusion in 510(k)s.

Christian Smith, Director of New Business Development within Smith Associates, reached out to Net Medical with the idea of working alongside their family-owned company to help small business succeed in getting their medical devices cleared. Along with founders EJ and Yolanda Smith, they have put together over 280 successful 510k clearances and countless PMA's across all Centers for Devices and Radiological Health (CDRH) at the FDA.

Net Medical CEO Dick Govatski said, "We're delighted with this valuable new partnership. Manufacturers of rapid antigen and PCR tests need custom designed protocols that can be submitted to the FDA for Over the Counter (OTC) products that are more readily available for consumers to check on and monitor their condition. This venture with Smith Associates is an important growth area for Net Medical."

For more information, call 505-255-1999 X 320. Visit www.netmedical.com. Email ir@netmedical.com.

About Net Medical - publicly traded (OTC Pink:NMXS) since 1999.

Net Medical has two operating units. Net Medical Labs is a moderate complex CLIA certified lab that specializes in virus and infection testing and diagnostics. The company's mobile fleet of vans provide COVID and flu testing in New Mexico for schools, companies, homeless shelters and nursing homes. The company provides a unique Test-To-Treat program for home and office care that combines both diagnostic and pharmaceutical services that are particularly valuable in rural communities. The lab also serves as a reference lab for physician offices and other facilities that lack services for complex virus diagnostics. Net Medical Xpress provides telemedicine solutions for hospitals, nursing homes, specialty hospitals and other medical facilities. The company maintains a 24/7/365 call center, a team of software developers and telemedicine platforms.

Forward-Looking Statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are the company's current expectations about future events and can be identified by terms such as "plans," "expect," "may," "anticipate," "intend," "should be," "will be," "is likely to," "believes," and similar expressions referring to future periods. The company believes any expectations reflected in the forward-looking statements are reasonable but cannot guarantee future results, level of activity, performance or achievements. Actual results may differ materially from those expressed or implied in the forward-looking statements.

SOURCE: Net Medical Xpress Solutions, Inc.


View source version on accesswire.com:
https://www.accesswire.com/703915/Net-Medical-Announces-Joint-Venture-with-Leading-FDA-Regulatory-Firm-Smith-Associates

population comparison of nm vs az.....
size(2021):
nm 2.1 million
az 7.2 million
or
az is 3.5 time of az.

education brief: Marketing Authorization Using the De Novo Review Pathway....
pertaining to FDA 510(k) and BioFire Respiratory Panel 2.1 (RP2.1).
https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-sars-cov-2-diagnostic-test-using-traditional-premarket-review-process
my favoriet:
"it is the first SARS-CoV-2 diagnostic test that will be permitted to be marketed beyond the public health emergency."
"The grant of the De Novo request for this test is based on additional data showing validation beyond what is needed for emergency use authorization. The FDA reviewed data from a clinical study of more than 500 test samples and a variety of analytical studies, which demonstrated a reasonable assurance that the BioFire RP2.1 was safe and effective at identification and differentiation of various respiratory viral and bacterial pathogens. "

I see a news icon

$NMXS Net Medical Expands Testing Facilities as Reported Covid-19 Cases Show IncreasePress Release | 06/01/2022

ALBUQUERQUE, NM / ACCESSWIRE / June 1, 2022 / Net Medical Xpress (OTC PINK:NMXS) announced today the company has expanded its program of COVID-19 testing amid an increase in the number of positive cases being reported.
Net Medical Xpress Solutions, Inc., Wednesday, June 1, 2022, Press release picture

Net Medical's Test-to-Treat program COVID-19 program has now been expanded to Arizona. Simultaneously, in conjunction with the Department of Health in New Mexico, the company‘s Test-to-Treat program is fully operational.

Net Medical President Rafael Rubio said, "It's the first time we have used our proprietary Telemed platform to offer physician services directly to consumers. Previously, our Telemed program was limited to our extensive hospital network for neurology, cardiology, and other highly specialized medical services. This comes at a time when we are seeing an upturn in COVID-19 cases in our test results.

"Our direct-to-consumer physician service is especially important and needed in rural areas where physician services tend to be limited. We have modified our platform to reach patients via their smart phones, tablets and computers for a face-to-face visit by our prescribing physicians.

"Patients are delighted with the overall convenience, ease of use and ready availability of physician prescribed antiviral medications through our arrangement with Walgreen's Federal Express delivery system. The average Telemed visit takes less than 10 minutes. Qualified patients can receive their medication at home within a day.

Rubio continued, "The home testing and prescription service is the future for many medical situations. It's amazing to see how effective this program is for patients without having to leave home when they are not feeling well. We expect Net Medical to expand our services based on new developments."

For more information, call 505-255-1999 X 320. Visit www.netmedical.com. Email ir@netmedical.com.

About Net Medical - publicly traded (OTC PINK:NMXS) since 1999.

Net Medical has two operating units. Net Medical Labs is a moderate complex CLIA certified lab that specializes in virus and infection testing and diagnostics. The company's mobile fleet of vans provide COVID and flu testing in New Mexico for schools, companies, homeless shelters and nursing homes. The company provides a unique Test-To-Treat program for home and office care that combines both diagnostic and pharmaceutical services that are particularly valuable in rural communities. The lab also serves as a reference lab for physician offices and other facilities that lack services for complex virus diagnostics. Net Medical Xpress provides telemedicine solutions for hospitals, nursing homes, specialty hospitals and other medical facilities. The company maintains a 24/7/365 call center, software developers and telemedicine platforms.

Forward-Looking Statements

This press releasecontainsforward-looking statements within the meaning ofSection 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are the company's currentexpectations about future events and can be identified by terms such as "plans," "expect," "may," "anticipate," "intend," "should be," "will be," "is likely to," "believes," and similarexpressionsreferring tofuture periods. The company believes any expectations reflected in the forward-looking statements are reasonable but cannot guaranteefuture results, level of activity, performance or achievements. Actual results may differ materially from those expressed or implied in the forward-looking statements.

SOURCE: Net Medical Xpress Solutions, Inc.


View source version on accesswire.com:
https://www.accesswire.com/703489/Net-Medical-Expands-Testing-Facilities-as-Reported-Covid-19-Cases-Show-Increase

beast

Net Medical President Rafael Rubio said.........
"It's the first time we have used our proprietary Telemed platform to offer physician services directly to consumers. Previously, our Telemed program was limited to our extensive hospital network for neurology, cardiology, and other highly specialized medical services. This comes at a time when we are seeing an upturn in COVID-19 cases in our test results"
https://www.otcmarkets.com/stock/NMXS/news/Net-Medical-Expands-Testing-Facilities-as-Reported-Covid-19-Cases-Show-Increase?id=359547

New highs

Printing .50s!

a bit different view.....
for people think they knew,at least in my case,and my odds of being right?more than 66%,i hope.

Silence is golden,
steady climb for the people in the know

ready

$NMXS Net Medical Announces New Orthopedic Infection Testing ServicePress Release | 05/24/2022

ALBUQUERQUE, NM / ACCESSWIRE / May 24, 2022 / Net Medical Xpress (OTC PINK:NMXS) announced today that it is preparing to launch a new testing service to support orthopedic surgeons in dealing with infection. CEO Dick Govatski said, "We are pleased to announce we are pairing with bioMérieux, a world leader in the field of in vitro diagnostics, to offer their new Joint Infection Panel to the orthopedic surgeon community.
Net Medical Xpress Solutions, Inc., Tuesday, May 24, 2022, Press release picture

"This is an important new tool in helping surgeons worldwide to detect and deal with threats of infection. The testing involves surgeons taking samples of synovial fluid from a patient's joint for us to run the tests in our lab here in Albuquerque. Our proprietary software is an essential component in linking with the bioMérieux technology.

"We expect our new orthopedic service to become a premier product of Net Medical. We currently anticipate launching the service in July," Govatski said.

Earlier this month, bioMérieux received De Novo authorization from the US Food and Drug Administration (FDA) for its BIOFIRE® Joint Infection (JI) Panel. The panel tests for 31 pathogens implicated in most acute joint infections. It includes 8 antimicrobial resistance (AMR) genes to optimize antibiotic therapy and stewardship.

Joint infections are medical emergencies that can involve either native or prosthetic joints. They can occur at all ages leading to functional joint impairment or long-lasting disability. In some cases, they can even be life- threatening. As the number of joint replacements increases, the threat of prosthetic joint infections is rising globally.

Optimal treatment of joint infections depends on a rapid and accurate diagnosis. Until now, diagnosis of joint infections has been challenging as available diagnostic methods provide variable accuracy, may have long turnaround times and are often negatively impacted by prior antimicrobial therapy.

The new BIOFIRE® JI Panel allows healthcare providers to quickly identify pathogens commonly found in patients with suspected joint infections, along with AMR genes to optimally guide antibiotic therapy, all in one simple rapid test. With a rapid turnaround time of about 1 hour and a broad panel menu of 39 targets, the BIOFIRE® JI Panel addresses unmet needs in joint infection diagnostics. Through fast and accurate results, the BIOFIRE® JI Panel may provide more informed decision-making for pathogen-guided management of patients with joint infections.

About bioMerieux

bioMerieux has been a major global player in the field of diagnostics for infectious diseases for more than 55 years. Please visit their website at https://www.biomerieux.com and www.biofiredx.com.

For more information, call 505-255-1999 X 320. Visit www.netmedical.com. Email ir@netmedical.com

About Net Medical - publicly traded (OTC PINK:NMXS) since 1999.

Net Medical has two operating units. Net Medical Labs is a moderate complex CLIA certified lab that specializes in virus and infection testing and diagnostics. The company's mobile fleet of vans provide COVID and flu testing in New Mexico for schools, companies, homeless shelters and nursing homes. The company provides a unique Test-To-Treat program for home and office care that combines both diagnostic and pharmaceutical services that are particularly valuable in rural communities. The lab also serves as a reference lab for physician offices and other facilities that lack services for complex virus diagnostics. Net Medical Xpress provides telemedicine solutions for hospitals, nursing homes, specialty hospitals and other medical facilities. The company maintains a 24/7/365 call center, software developers and telemedicine platforms.

Forward-Looking Statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are the company's current expectations about future events and can be identified by terms such as "plans," "expect," "may," "anticipate," "intend," "should be," "will be," "is likely to," "believes," and similar expressions referring to future periods. The company believes any expectations reflected in the forward-looking statements are reasonable but cannot guarantee future results, level of activity, performance or achievements. Actual results may differ materially from those expressed or implied in the forward-looking statements.

SOURCE: Net Medical Xpress Solutions, Inc.


View source version on accesswire.com:
https://www.accesswire.com/702436/Net-Medical-Announces-New-Orthopedic-Infection-Testing-Service

syndromic approach.......
How Does Syndromic Infectious Disease Testing Work?
https://www.biofiredx.com/syndromic-testing/

hidden gem
same potential as other hidden gem PXHI

worth dollars

strong

possibilities.......
before you wager your hard earned money.good luck.
from quarterly:
"$3.2 million medical billing allowance"
"backstop contract with the State of New Mexico that runs through 2024 to reimburse unpaid insurance claims for community Covid-19 testing."
or
recoverable eps = 1.5c per q(using 5 quarters,all 2021 and 1q 2022)

the 1q,2022 adjusted eps can be as high as
adjusted eps of 3.5c =2c(eps)+1.5c(recoverable eps),that is 14c annualized.

so the million dollar question becomes: how likely is the 14c and stock price?
at 0% chance,the stock is worth 40c=8c(generic eps,forward looking)x5*(pe)
at 50% chance,the stock is worth 55c=11c(8c+3c reimbursement)x5
at 100% chance,the stock is worth 70c= 14c x 5
*pe of 5 is used for a high growth and uncovered penny stock.

or
price at 40c and below:
market assumes 0% of reimbursement
0% chance of covid-testing duplication in other states

watch out:
stock price $1.40 = 14c(100% recovery)*2(1st duplication)*5(with no pe expansion)
again,this could be "a pie in the sky" and i may be dreaming!

ps-i am long on the stock.

https://www.stockscores.com/chart.asp?TickerSymbol=nmxs&TimeRange=1825&Interval=m&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

https://finance.yahoo.com/news/net-medicals-test-treat-off-123000353.html

https://finance.yahoo.com/news/net-medicals-test-treat-off-123000353.html

https://finance.yahoo.com/news/net-medicals-test-treat-off-123000353.html

Thanks

quarterly report is out........
cash $682K
a/r $1.6 million
plus
"medical billing allowance of $3.16 million"
and nothing more important than(which was missing/unqualified last q)
"The Company has a backstop contract with the State of New Mexico that runs through 2024 to reimburse unpaid insurance claims for community Covid-19 testing."

Lol ascm top bid trying for shares

Wrong chart?

https://www.barchart.com/stocks/quotes/ATMFF/technical-chart?plot=CANDLE&volume=total&data=WO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=ATMFF&grid=1&height=500&studyheight=100

Gtsm was professionally trying to get some yesterday on the bid

Upticking ascm once someone hit them

strong churn

Don’t sleep on it

This guy has 86,000 twitter followers and is posting this excellent post as one of his alerts this weekend.


https://twitter.com/socialstartnow1?s=11&t=YALZq_Cqfy4KWXjlcBH-NQ

Yup all the indicators have had a good chance to cool off after the last two.

It’s par for the course for ASCM to show up on the third day of a run. Wouldn’t be surprised if they put out some more good news on Monday.

We weeded out the traders today.